Vaxart Inc VXRT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:34 PM EST
7.52quote price arrow up+0.37 (+5.17%)
Volume
4,987,568
52 week range
1.08 - 24.90

...

Loading . . .

KEY STATS

  • Open7.41
  • Day High7.64
  • Day Low7.08
  • Prev Close7.15
  • 52 Week High24.90
  • 52 Week High Date02/02/21
  • 52 Week Low1.08
  • 52 Week Low Date03/16/20
  • Market Cap885.62M
  • Shares Out117.77M
  • 10 Day Average Volume9.24M
  • Dividend-
  • Dividend Yield-
  • Beta0.03
  • 1 Year % Change160.31

RATIOS/PROFITABILITY

  • EPS (TTM)-0.35
  • P/E (TTM)-21.48
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-15.776M
  • ROE (MRQ)-32.90%
  • Revenue (MRQ)7.61M
  • Gross Margin (MRQ)5.38%
  • Net Margin (MRQ)-325.64%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/12/2021
  • Ex Div Date11/09/2012
  • Div Amount6.648
  • Split Date-
  • Split Factor-

QUOTE FINDER

Profile

MORE
Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial;...
Wouter Latour M.D.
Chairman
Andrei Floroiu
Chief Executive Officer
Margaret Echerd
Chief Accounting Officer
Address
385 Oyster Point Boulevard, Suite 9A
South San Francisco, CA
94080
United States